New forecast predicts drug sales to grow nearly five percent annually for the pharma/biotech sector

WASHINGTON - June 24, 2015 - PRLog -- According to the “EvaluatePharma World Preview 2015, Outlook to 2020” report, prescription sales are expected to increase 5 percent annually over the next five years across the United States  and Europe. The projected increase is fueled by the emergence of new therapeutic breakthroughs and drug approvals. In fact, the FDA reached a record high in 2014 approving 50 new therapies, eight of which are potential blockbusters expected to garner sales of more than $1 billion five years after launch.

Report highlights include:

·         • Gobal drug sales could potentially reach $1 trillion by 2020 with a CAGR of 4.8 percent between 2014 and 2020

·         •  The US prescription market had an increase of 8.9 percent in sales; Europe had a 2.4 percent  growth

·         •  R&D pipeline values increase to $492.8 billion from $418.5 billion in 2014; Gilead’s hepatitis C drug combo is valued highest at $24.8 billion

·         •  Abbvie’s Humira is the top selling product of 2014, posting stellar sales of approximately $13.9 billion. Gilead’s Sovaldi came in second with sales totaling $10 billion

·         •  Novartis will remain the top dog in the pharmaceutical industry; the company earned $53.3 billion from prescription drug sales

·         •  M&A transactions were valued at $116 billion in 2014; value of venture financing deals amounted to $8.2 billion representing a 36 percent increase

“Any fears that the pharmaceutical industry might be heading towards a slowdown after the last two years of phenomenal growth can be put to rest for now,” said Lisa Urquhart, Editor of EP Vantage, the editorial arm of Evaluate. “However, for the industry to sustain this impressive growth they will have to make compromises around global pricing and market access. As such, pharmaceutical companies need to either accept lower prices for its products, or persuade payers that the therapeutic benefits outweigh the cost of disease.”

CANDIDATES WHO WANT TO BREAK INTO A PHARMACEUTICAL SALES CAREER!

Based on the forecasts of sustained growth in the pharmaceutical and biotech industry, now is the time to enter this wonderfield field! New product launches will bolster the need for both certified and qualified individuals to promote the company's  product portfolio. When industry leaders look for new candidates for sales/marketing positions, they look toward individuals that are industry trained. Companies tend to recruit candidates that have the background to market their product both proficiently and efficiently.

The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Pharmaceutical sales candidates who have this training will differentiate themselves from other applicants looking for open positions. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information or visit the website at http://napsronline.org/